BusinessOtonomy to Present at Piper Jaffray Healthcare ConferenceBy Nasdaq OMXNov 22, 2017, 12:30 PM UTC
BusinessOtonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's DiseaseBy Nasdaq OMXAug 30, 2017, 11:00 AM UTC
BusinessOtonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis ExternaBy Nasdaq OMXJul 18, 2017, 11:30 AM UTC
BusinessOtonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis ExternaBy Nasdaq OMXJan 5, 2017, 12:01 PM UTC
BusinessOtonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis ExternaBy Nasdaq OMXJan 5, 2017, 12:01 PM UTC
BusinessOtonomy Reports Third Quarter 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXNov 3, 2016, 8:13 PM UTC
BusinessOtonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing LossBy Nasdaq OMXJan 26, 2016, 12:05 PM UTC
